Lunai Bioworks Inc. LNAI
Last close
0.29
2026-10-23
Market cap
$10.7M
2026-03-31 share count
52-week range
0.23 - 13.28
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.08
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | $42.8K |
| Cost of revenue | — | — | — | — | — | — | — | — | — | $5.3K |
| Gross profit | — | — | — | — | — | — | — | — | — | $37.5K |
| R&D | $537.4K | $2.7M | $4.2M | $8.4M | $15.7M | $4.7M | $2.5M | $617.0K | $62.8K | $804.2K |
| SG&A | $17.9M | $24.6M | $15.3M | $14.3M | $7.6M | $7.1M | $8.4M | $3.9M | $933.8K | $1.2M |
| Total operating expenses | $189.0M | $81.6M | $38.6M | $116.1M | $23.4M | $11.9M | $11.0M | $5.3M | $2.4M | $2.2M |
| Operating income | -$189.0M | -$81.6M | -$38.6M | -$116.1M | -$23.4M | -$11.9M | -$11.0M | -$5.3M | -$2.4M | -$2.1M |
| Interest expense | $725.7K | $1.0M | $580.3K | $122.0K | $379.6K | $104.3K | $43 | $143.3K | — | $2.4K |
| Pre-tax income | -$178.0M | -$88.4M | -$39.7M | -$113.4M | -$26.8M | -$11.4M | -$18.0M | -$6.4M | -$2.2M | -$2.2M |
| Income tax | $1.5K | $0 | — | $34 | $125.3K | — | — | $111.7K | $64.9K | $462.8K |
| Net income | -$178.0M | -$88.4M | -$39.7M | -$113.4M | -$26.7M | -$11.4M | -$18.0M | -$6.3M | -$2.1M | -$1.7M |
| EPS, basic | -1.08 | -0.91 | -0.71 | -2.16 | — | — | — | — | — | — |
| EPS, diluted | -1.08 | -0.91 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 |
| Shares, diluted (wtd. avg.) | 165.1M | 97.5M | 56.3M | 52.5M | — | — | — | — | 12.3M | 9.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $92.7K | $220.5K | $1.9M | $9.2M | $20.7M | $8.7M | $12.3M | $15.6M | $3.9M | $23.4K |
| Total current assets | $1.0M | $2.0M | $2.6M | $9.6M | $20.9M | $8.9M | $12.5M | $15.8M | $4.2M | $732.5K |
| Property, plant and equipment | $367.8K | $482.1K | $509.0K | $586.5K | $719.4K | $778.1K | $687.5K | $27.4K | — | — |
| Goodwill | $6.0M | $159.3M | $11.6M | $11.6M | $11.6M | $11.6M | $11.6M | $11.6M | — | — |
| Other intangibles | $166.0K | $30.0K | $39.7K | $44.3K | $65.9K | $77.3K | $93.3K | $111.5K | $124.4K | $135.7K |
| Total assets | $8.2M | $163.1M | $58.3M | $84.6M | $189.6M | $178.1M | $179.9M | $182.5M | $4.5M | $870.8K |
| Total current liabilities | $29.2M | $30.3M | $11.0M | $6.5M | $1.9M | $1.3M | $1.1M | $873.7K | $3.0M | $1.5M |
| Long-term debt | — | — | — | — | — | — | — | — | — | $102.9K |
| Total liabilities | $29.6M | $31.2M | $11.8M | $12.0M | $14.9M | $11.8M | $6.8M | $23.8M | $3.0M | $1.5M |
| Retained earnings | -$510.5M | -$332.5M | -$244.0M | -$204.3M | -$90.9M | -$64.2M | -$52.8M | -$34.8M | -$28.4M | -$26.3M |
| Total equity | -$21.3M | $132.0M | $46.5M | $72.6M | $174.7M | $166.3M | $173.1M | $158.7M | $1.5M | -$637.4K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.9M | -$11.0M | -$11.8M | -$15.7M | -$20.6M | -$10.5M | -$8.5M | -$4.3M | -$1.2M | -$1.5M |
| Depreciation and amortisation | $129.1K | $121.9K | $113.5K | $123.6K | $123.5K | $108.6K | $71.7K | $18.5K | $14.5K | $27.4K |
| Stock-based compensation | $3.3M | $4.7M | $3.5M | $5.2M | $1.3M | $884.7K | $2.1M | $63.7K | — | — |
| Capital expenditure | — | $70.4K | $29.8K | $5.2K | $48.9K | $184.5K | $716.7K | $30.0K | — | — |
| Investing cash flow | -$500.0K | -$1.3M | -$29.8K | -$5.2K | -$48.9K | -$184.5K | -$716.7K | -$575.7K | -$196.1K | $1.1M |
| Financing cash flow | $8.4M | $10.5M | $4.5M | $4.3M | $32.6M | $7.2M | $6.0M | $16.7M | $5.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001731122-25-001316.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.8K | — | — | — | — | — | — | — | — | — |
| Gross profit | $37.5K | — | — | — | — | — | — | — | — | — |
| Net income | -$1.7M | -$2.1M | -$6.3M | -$18.0M | -$11.4M | -$26.7M | -$113.4M | -$39.7M | -$88.4M | -$178.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Delisting notice Item 3.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |